Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Mathew Aby J., Executive Vice President and Chief Scientific Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold 10,589 shares of the company’s common stock. The transaction, which took place on April 1, 2025, was executed at a price of $22.66 per share, amounting to a total value of $239,946. According to InvestingPro data, the stock has experienced significant volatility recently, with a -9.13% return over the past week, though maintaining a robust 37.3% gain over the past year.
Following this sale, Mathew Aby J. holds 309,576 shares directly. This sale was conducted under a Rule 10b5-1 trading plan, which was established to cover tax withholding obligations related to the vesting of restricted stock. The company maintains strong financial health with a current ratio of 4.54, indicating ample liquidity to meet short-term obligations. InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about BLFS’s financial position through comprehensive Pro Research Reports.
In other recent news, BioLife Solutions reported strong fourth-quarter financial results, with revenue reaching $22.7 million, surpassing analyst estimates of $21.3 million. The company posted a net loss of $2.0 million, or $0.04 per share, which was smaller than expected. For the entire year of 2024, BioLife Solutions achieved total revenue of $82.3 million, excluding $37.7 million from discontinued operations, and a net loss of $11.4 million. The Cell Processing segment showed a 31% year-over-year revenue increase, marking its fifth consecutive quarter of growth.
Analysts have taken note of BioLife’s performance, with KeyBanc maintaining an Overweight rating and a $33 target, while H.C. Wainwright and Benchmark both set a $30 price target with Buy ratings. BioLife’s management projects 2025 revenue to range between $95.5 million and $99 million, indicating a 16-20% growth. The company’s biopreservation media is now included in 17 approved cell and gene therapies, with potential for further approvals and expansions. BioLife’s recent focus on its core business, following divestitures, has contributed to its improved financial outlook and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.